Drug intelligence / Profile preview

RR-M09

Development stage: Preclinical
Lead developer: RocRock Biotechnology
Modality: CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies

Overview

RR-M09 is an experimental Chimeric Antigen Receptor Macrophage (CAR-M) cell therapy being developed by RocRock Biotechnology for the treatment of pulmonary fibrosis. CAR-M therapy involves engineering macrophages to express a chimeric antigen receptor, allowing them to specifically target and potentially clear fibrotic tissue or modulate the inflammatory environment in the lungs. As of early 2024, RR-M09 is in the preclinical stage of development, specifically undergoing proof-of-concept or animal studies. The specific molecular target of the CAR in RR-M09 has not been publicly disclosed by the developer.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on RR-M09.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RR-M09.

Explore the full profile